Menta Capital Has Boosted Its Citizens Finl Group (CFG) Holding; Baker Bros Advisors LP Holding in Neurocrine Biosciences (NBIX) Decreased by $15.21 Million as Stock Declined

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Logo

Menta Capital Llc increased its stake in Citizens Finl Group Inc (CFG) by 79.86% based on its latest 2018Q4 regulatory filing with the SEC. Menta Capital Llc bought 11,500 shares as the company’s stock rose 1.15% with the market. The hedge fund held 25,900 shares of the finance company at the end of 2018Q4, valued at $770,000, up from 14,400 at the end of the previous reported quarter. Menta Capital Llc who had been investing in Citizens Finl Group Inc for a number of months, seems to be bullish on the $16.06 billion market cap company. The stock decreased 0.51% or $0.18 during the last trading session, reaching $34.88. About 1.03 million shares traded. Citizens Financial Group, Inc. (NYSE:CFG) has declined 15.35% since April 15, 2018 and is downtrending. It has underperformed by 19.72% the S&P500. Some Historical CFG News: 31/05/2018 – Citizens Financial Group, Inc. To Expand Mortgage Banking Business With Acquisition Of Franklin American Mortgage Company; 31/05/2018 – CITIZENS FINANCIAL GROUP INC – DEAL FOR FOR $511 MLN IN CASH; 20/04/2018 – Citizens Financial Group 1Q EPS 78c; 31/05/2018 – CITIZENS FINANCIAL GROUP INC – COMBINED MORTGAGE BUSINESS WILL BE LED BY ERIC SCHUPPENHAUER, CURRENT CITIZENS PRESIDENT OF HOME MORTGAGE; 20/04/2018 – Citizens Financial Group, Inc. Reports First Quarter Net Income of $388 Million and Diluted EPS of $0.78; 31/05/2018 – CITIZENS FINANCIAL TO ACQUIRE FRANKLIN AMERICAN MORTGAGE; 21/03/2018 – Citizens Financial Group Announces Prime Rate Change; 24/05/2018 – CITIZENS FINANCIAL – REDEMPTION PRICE FOR NOTES WILL BE EQUAL TO 100% OF NOTES REDEEMED, PLUS ANY ACCRUED & UNPAID INTEREST TO, BUT EXCLUDING DATE; 31/05/2018 – Citizens Financial Group Unit Citizens Bank N.A. Will Purchase Assets for $511M in Cash; 14/05/2018 – Casablanca Lender CFG Set to Join Moroccan Push Into West Africa

Baker Bros Advisors Lp decreased its stake in Neurocrine Biosciences Inc. (NBIX) by 22.68% based on its latest 2018Q4 regulatory filing with the SEC. Baker Bros Advisors Lp sold 214,269 shares as the company’s stock declined 11.62% while stock markets rallied. The hedge fund held 730,355 shares of the health care company at the end of 2018Q4, valued at $52.16 million, down from 944,624 at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Neurocrine Biosciences Inc. for a number of months, seems to be less bullish one the $7.74B market cap company. The stock decreased 1.25% or $1.08 during the last trading session, reaching $85.16. About 115,781 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has declined 6.23% since April 15, 2018 and is downtrending. It has underperformed by 10.60% the S&P500. Some Historical NBIX News: 30/04/2018 – Neurocrine 1Q Loss $41.8M; 10/04/2018 – AbbVie: Elagolix Clinical Trial Program Largest Prospective Randomized Endometriosis Trial Conducted to Date; 13/03/2018 – ABBVIE INC – RESULTS DEMONSTRATED ELAGOLIX, WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO; 30/04/2018 – NEUROCRINE BIO 1Q REV. $71.1M, EST. $65.4M; 16/03/2018 – $NBIX has raised the price of Ingrezza 40mg capsule by 9% effective 3/15/18, meanwhile $TEVA Austedo has surpassed on TRx. [h/t Cowen & ISI]; 30/04/2018 – Neurocrine 1Q Loss/Shr 47c; 27/04/2018 – AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) An; 10/05/2018 – Neurocrine Bio Presenting at Bank of America Conference May 15; 10/04/2018 – AbbVie Remains Confident in NDA and Continues to Work With FDA to Bring Elagolix to Patients; 30/04/2018 – NEUROCRINE BIO 1Q LOSS/SHR 47C, EST. LOSS/SHR 30C

Menta Capital Llc, which manages about $2.11 billion and $269.78M US Long portfolio, decreased its stake in Radiant Logistics Inc (NYSEMKT:RLGT) by 165,826 shares to 37,586 shares, valued at $160,000 in 2018Q4, according to the filing. It also reduced its holding in Allstate Corp (NYSE:ALL) by 4,100 shares in the quarter, leaving it with 2,457 shares, and cut its stake in Palo Alto Networks Inc (NYSE:PANW).

Investors sentiment increased to 0.98 in Q4 2018. Its up 0.11, from 0.87 in 2018Q3. It increased, as 54 investors sold CFG shares while 188 reduced holdings. 71 funds opened positions while 165 raised stakes. 431.43 million shares or 0.06% more from 431.19 million shares in 2018Q3 were reported. Cordasco Financial Networks owns 67 shares. Barry Inv Advsrs Limited Liability Company invested 2.42% of its portfolio in Citizens Financial Group, Inc. (NYSE:CFG). Fiera Cap reported 0% stake. Scout has invested 0.97% of its portfolio in Citizens Financial Group, Inc. (NYSE:CFG). 134,000 were reported by State Treasurer State Of Michigan. Fmr Lc reported 1.60 million shares stake. Arizona State Retirement has 0.08% invested in Citizens Financial Group, Inc. (NYSE:CFG) for 220,112 shares. 319,968 were reported by Bancorporation Of Nova Scotia. Price T Rowe Assoc Md holds 822,698 shares. Advisory Services Ntwk Limited Liability Co holds 0% or 1,133 shares. Kennedy Capital Mgmt holds 0.08% or 108,346 shares in its portfolio. Haverford Trust invested 0.01% of its portfolio in Citizens Financial Group, Inc. (NYSE:CFG). Nuwave Invest Mngmt Limited Liability Com has invested 0% in Citizens Financial Group, Inc. (NYSE:CFG). Glenmede Na has 0.19% invested in Citizens Financial Group, Inc. (NYSE:CFG) for 1.31M shares. Massachusetts-based Panagora Asset Mgmt Inc has invested 0.62% in Citizens Financial Group, Inc. (NYSE:CFG).

More recent Citizens Financial Group, Inc. (NYSE:CFG) news were published by: 247Wallst.com which released: “Inverted Yield Curve Could Threaten Regional Banks’ High Dividends – 24/7 Wall St.” on March 25, 2019. Also Benzinga.com published the news titled: “Barron’s Picks And Pans: Alibaba (NYSE:BABA), Citizens Financial (NYSE:CFG), FAANG Stocks And More – Benzinga” on October 21, 2018. Investorplace.com‘s news article titled: “15 Stocks to Buy Leading the Financial Charge – Investorplace.com” with publication date: April 02, 2019 was also an interesting one.

Since October 23, 2018, it had 2 buys, and 0 sales for $614,440 activity. The insider KOCH CHARLES JOHN bought 14,000 shares worth $508,480.

Since October 29, 2018, it had 0 buys, and 24 sales for $15.26 million activity. ROBERTS EIRY had sold 1,857 shares worth $156,159 on Tuesday, January 8. On Wednesday, February 6 Lippoldt Darin sold $66,063 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 791 shares. Shares for $240,125 were sold by Bozigian Haig P. on Monday, February 4. Another trade for 762 shares valued at $63,673 was made by Gano Kyle on Wednesday, February 6. ABERNETHY MATT sold 1,178 shares worth $106,020. POPS RICHARD F had sold 4,124 shares worth $376,790.

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Nasdaq.com which released: “Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology – Nasdaq” on March 28, 2019, also Nasdaq.com with their article: “1 Biotech That Biogen Should Buy … but Probably Won’t – Nasdaq” published on April 04, 2019, Seekingalpha.com published: “Neurocrine Biosciences: Rapid Pipeline Expansion Underway – Seeking Alpha” on March 19, 2019. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Nasdaq.com and their article: “Noteworthy Thursday Option Activity: NBIX, CRUS, C – Nasdaq” published on March 21, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 12/12/2018: NBIX, TLGT, ADAP – Nasdaq” with publication date: December 12, 2018.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on April, 29. They expect $-0.92 earnings per share, down 95.74% or $0.45 from last year’s $-0.47 per share. After $0.19 actual earnings per share reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -584.21% negative EPS growth.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart